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death of the affected cell.
More generally, there is now a fertile
and sometimes fractious dispute as to
the importance of genome instability in
tumorigenesis. On the one extreme,
some have argued aneuploidy is the fun-
damental mechanism of tumorigenesis,
with activated oncogenes and wrecked
tumor suppressors merely a sideshow to
distract gullible molecular biologists
(Duesberg, 1999). More mainstream,
however, is the important debate over
whether genome instability is a perva-
sive and sustained attribute of tumor
cells, perhaps driven by oncoproteins
like Myc, or rather a relic of some past
genomic mayhem  (such as telomere
erosion) that has long since stabilized
(DePinho, 2000). In this latter case,
genome instability would be the
sideshow to the underlying proliferative
and antiapoptotic lesions that drive the
inexorable proliferation and enforced
survival of the evolving tumor cell.
Defining a direct link between oncogenic
lesions and genomic instability would
certainly keep both camps happy: the
testing of intriguing studies like those of
Vafa et al. in animal models may settle
the matter once and for all.
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Thinking beyond the tumor cell: Nf1 haploinsufficiency 
in the tumor environment
Deletion of both copies of the Nf1 gene in Schwann cells combined with Nf1 heterozygosity in the tumor environment pro-
motes neurofibroma formation in mice.
Tumor cells in vivo do not grow in isolation
and are intimately associated with non-
neoplastic cells such as endothelial cells,
fibroblasts, and inflammatory cells.
Together, tumor cells and their neighbors
form a complex tissue mass in which a
network of heterotypic cell interactions
occurs (Hanahan and Weinberg, 2000).
The net balance between growth-promot-
ing and growth-inhibitory interactions like-
ly determines whether a given host envi-
ronment is permissive or resistant to
tumor formation. A thorough understand-
ing of these heterotypic cell interactions
may therefore provide the basis for novel
anticancer therapies aimed at increasing
the resistance of the host environment.
In a recent paper, Zhu and coworkers
focused on neurofibromas, benign tumors
of the peripheral nerve sheath, as models
for study of heterotypic cell interactions
(Zhu et al., 2002). Neurofibromas are
unique among tumors with respect to the
extent of their cellular heterogeneity.
Neurofibromas invariably contain all of the
cell types found in normal peripheral
nerves (axonal processes of neurons,
Schwann cells, perineurial cells, fibrob-
lasts, and mast cells) (Figure 1). The cel-
lular heterogeneity of neurofibromas is so
striking that some in the past argued that
these lesions were actually hyperplasias,
not tumors.
Neurofibromas are the major feature
of the common familial cancer syndrome
neurofibromatosis type 1 (NF1). Patients
with NF1 inherit a germline mutation in
one copy of the NF1 gene, which encodes
the protein neurofibromin, a member of
the Ras-specific GTPase-activating pro-
tein (RasGAP) family (Buchberg et al.,
1990; Xu et al., 1990). When a somatic
mutation eliminates the remaining wild-
type NF1 gene copy, tumor formation is
initiated. The fundamental problem with
NF1-deficient tumor cells is thought to be
that Ras, a key component of many
growth factor signaling pathways, is con-
stitutively activated, resulting in increased
cell proliferation and/or cell survival.
The first obstacle that Zhu and co-
workers had to overcome was to create a
tractable mouse model of neuro-
fibromas. While Nf1−/− mice die in
midgestation, Nf1+/− mice are cancer
prone, developing two tumors associat-
ed with NF1 (pheochromocytoma and
myeloid leukemia) but not neurofibro-
mas (Brannan et al., 1994; Jacks et al.,
1994). Based on the hypothesis that
somatic Nf1 mutation is the rate-limiting
step in neurofibroma formation in Nf1+/−
mice, Cichowski and coworkers created
chimeric mice partially composed of Nf1−/−
cells (Cichowski et al., 1999). Nearly all of
these mice develop numerous neurofibro-
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mas that histologically resemble human
plexiform neurofibromas. (In humans,
neurofibromas of the plexiform subtype
occur almost exclusively in NF1 patients,
grow in the intraneural space of either a
plexus of nerves or multiple fascicles of a
medium to large nerve, and are prone to
malignant change.) The chimeric mouse
model, however, has its limitations: the
cell type in which Nf1 is deleted cannot be
controlled and these animals cannot easi-
ly be crossed to other mutant mouse
strains. Therefore, Zhu and coworkers
generated a conditional Nf1 mouse model
in which a floxed Nf1 allele is deleted by a
Cre transgene under control of the
Schwann cell-specific promoter, Krox-20.
All progeny with the Nf1flox/−;Krox20-cre
genotype develop plexiform neurofibro-
mas, confirming that the Schwann cell is
the cell of origin.
Loss of NF1 in Schwann cells pro-
vides a straightforward explanation for the
hyperproliferation of Schwann cells within
a neurofibroma, but it does not explain the
excess numbers of perineurial cells,
fibroblasts, and mast cells, nor does it
explain how these neighboring cells may
influence tumor development. To compli-
cate matters further, not all neighboring
cells are genetically equivalent. In NF1
patients and mice with a germline knock-
out of one Nf1 allele, all of the cells in the
body are heterozygous for NF1, raising
the question of whether heterozygous
neighboring cells can promote tumor
growth more efficiently than wild-type
neighboring cells. Implicit is the possibility
that heterozygous inactivation of NF1 has
functional consequences (haploinsuffi-
ciency).
The importance of tumor suppressor
gene haploinsufficiency in tumor cell biol-
ogy has only recently begun to draw
attention. Classically, a tumor suppressor
gene has been defined as a gene in which
mutation (or other functional inactivation)
of both copies is required for tumor forma-
tion, implying that only complete loss of
the gene product produces a cellular
defect. However, there is a growing list of
genes that encode proteins with tumor
suppressor activities (p53, p27Kip1, and
Dmp1) in which mutation of one copy of
the gene has functional consequences
(Cook and McCaw, 2000; Quon and
Berns, 2001). p53, for example, is a tran-
scription factor and well-known tumor
suppressor that plays a critical role in cell
cycle arrest and apoptosis. In a subset of
human tumors with p53 mutations and in
over half of tumors arising in Trp53+/−
mice, loss of heterozygosity at the p53
locus is not detected. Extensive analysis
of the murine Trp53+/− tumors revealed
that the remaining wild-type allele
appears to be structurally and functionally
intact, suggesting that p53 haploinsuffi-
ciency may promote tumor formation
(Venkatachalam et al., 1998). Importantly,
loss of both p53 alleles is more tumori-
genic than loss of one, indicating that in
the case of p53, haploinsufficiency is par-
tial. Quon and Berns have recently pro-
posed that all tumor suppressor genes
that are frequently mutated in sporadic
human cancers may show varying
degrees of haploinsufficiency, with some
genes showing strong effects and others
showing partial or weak effects (Quon
and Berns, 2001).
Since tumor suppressor gene hap-
loinsufficiency can provide a selective
advantage to tumor cells and/or their pre-
cursors, it is logical to consider whether
tumor suppressor gene haploinsufficiency
can alter the function of nonneoplastic
cells in the tumor environment.To address
this issue, Zhu and coworkers compared
the size and frequency of neurofibromas
occurring in Nf1flox/−;Krox20-cre mice in
which all neighboring cells are pheno-
typically heterozygous for Nf1 and
Nf1flox/flox;Krox20-cre mice in which all of
the neighboring cells are phenotypically
wild-type. In striking contrast to the wide-
spread plexiform neurofibromas of the
Nf1flox/−;Krox20-cre mice, the Nf1flox/flox;-
Krox20-cre mice only developed small,
infrequent hyperplastic lesions in the cra-
nial nerves (Figure 1). Although the num-
ber of mice in this study was limited, the
data supports the conclusion that Nf1 het-
erozygosity in the tumor environment pro-
motes neurofibroma formation.
What is the mechanism by which Nf1
heterozygosity in the tumor environment
exerts its effect on neurofibroma growth?
The first step toward answering this ques-
tion is to identify the relevant cell type(s) in
Figure 1. Nf1 heterozygosity in the tumor environment promotes neurofibroma formation in
mice
Peripheral nerves are composed of multiple nerve fascicles. Each nerve fascicle is divided into
the endoneurium, which contains axons (A), Schwann cells (SC), fibroblasts (F), mast cells (MC),
and collagen, and the perineurium, a layer of perineurial cells (PC), which forms the blood-
nerve barrier. In a wild-type mouse, deletion of both copies of the Nf1 gene in Schwann cells
results in hyperplasia but not frank neurofibroma formation. In contrast, deletion of both copies
of the Nf1 gene in Schwann cells from an Nf1+/− mouse leads to widespread plexiform neurofi-
bromas. Neurofibromas contain all of the cell types normally present in peripheral nerves as
well as abnormal Schwann cells, which have become dissociated from axons (DSC).
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which Nf1 heterozygosity is required to
see frank tumor formation. One candi-
date cell type is the mast cell. Nf1+/−
mast cells have been shown to hyper-
proliferate in vitro and in vivo in Nf1+/−
mice (Ingram et al., 2000). In comparing
peripheral nerves from Nf1flox/−;Krox20-
cre and Nf1flox/flox;Krox20-cre mice, Zhu
and coworkers noted a marked reduction
in mast cell infiltration in the hyperplastic
lesions from Nf1flox/flox;Krox20-cre mice rel-
ative to the tumors of Nf1flox/−;Krox20-cre
animals. They also found that mast cells
infiltrated preneoplastic peripheral nerves
of Nf1flox/−;Krox20-cre mice but not periph-
eral nerves of Nf1flox/flox;Krox20-cre or
Nf1+/− mice, suggesting that recruitment of
mast cells to peripheral nerves requires
both Nf1+/− mast cells and Nf1−/− Schwann
cells. The presence of Nf1+/− mast cells in
preneoplastic peripheral nerves as well
as in the plexiform neurofibromas led Zhu
and coworkers to speculate that Nf1+/−
mast cells may play a central role in the
initiation of neurofibromas.
In addition to infiltrating neurofibro-
mas, mast cells have been identified at
the periphery of several other human can-
cers such as melanoma, breast carcino-
ma, and colorectal adenocarcinoma.
During an acute inflammatory response,
mast cells release diverse factors capable
of inducing angiogenesis, remodeling the
extracellular matrix, and stimulating cell
proliferation: effects that hasten wound
healing but in a different context may pro-
mote tumor growth. Indeed, Hanahan’s
group has demonstrated that mast cells
and the inflammatory cell product matrix
metalloproteinase (MMP)-9 can con-
tribute to tumorigenesis in a mouse model
of squamous carcinoma (Coussens et al.,
1999, 2000). Thus, there is precedent for
implicating mast cells in tumor formation.
While the recruitment of mast cells in
the conditional neurofibroma model may
be influenced by their Nf1 genotype, wild-
type mast cells likely contribute to tumori-
genesis in other settings. For instance, in
the squamous carcinoma model noted
above, the tumor-promoting mast cells
were presumably wild-type. Furthermore,
in humans the vast majority of neurofibro-
mas (which are of the localized cutaneous
subtype and grow in the extraneural tis-
sue of the dermis and subcutis) are not
associated with NF1, yet these sporadic
neurofibromas contain abundant wild-
type mast cells (Scheithauer et al., 1999).
Perhaps there are species-specific differ-
ences that allow wild-type mast cells to
home to neurofibromas in humans but not
in mice.
The effects of Nf1 heterozygosity in
the tumor environment may not be due
solely to Nf1 haploinsufficiency in mast
cells, but interactions with other Nf1+/− cell
types may also be required. Prior work
has shown that Nf1+/− Schwann cells are
able to induce angiogenesis and are more
invasive than their wild-type counterparts
(Kim et al., 1997). In addition, embryonic
fibroblasts from Nf1+/− mice hyperprolifer-
ate, respond abnormally to wound
cytokines, and secrete higher amounts of
collagen in vitro. In vivo in Nf1+/− mice,
wounding incites an excessive prolifera-
tion of fibroblasts, leading to an increased
amount of granulation tissue (Atit et al.,
1999).
While focused on a model of an
inherited cancer syndrome, the work
from Zhu et al. raises the intriguing pos-
sibility that the genotype of the nonneo-
plastic cells comprising the microenvi-
ronment of sporadic tumors might also
influence the properties of the tumor, or,
indeed, might help determine whether a
tumor arises in the first place. Like the
tumor cells, such cells could undergo pro-
tumorigenic somatic mutations, or per-
haps more likely, their particular constel-
lation of inherited polymorphic alleles
might make them inherently more (or
less) capable of supporting tumor devel-
opment. This might shed new light on
how some cancer “modifier genes” might
affect cancer susceptibility in the general
population. Moreover, an increased
understanding of the role of these sup-
port cells might lead to new directions for
cancer therapy and prevention.
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